Quality Management 2017

Conclusion: Demonstrated PROS for MDMs

1. Decreases waiting time to treatment for H&N, pancreas, anus- rectal and gynecological cancers 2. Improves diagnostic/therapeutic paths and ensure application of guidelines: yes for prostate, breast and glioma 3. Changes treatments attitude and rate of intervention: yes for lung, breast and prostate 4. Garantees/facilitates timely access to physical/phycho-emotional rehabilitation programs: yes for prostate and breast 5. Helps and improves management of disease recurrence and timely access to support and palliative care 6. Helps enrollement in innovative and experimental therapies: yes for colo-rectal cancers, breast and prostate 7. Improves the education of professionals involved in patients care 8. Increases patients satisfaction: yes for prostate and breast 9. Improves survival: yes for lung, oesophageal, ovarian and HR prostate cancers 10. Guarantees a minor risk of law suits FM Boyle et al: J Clin Oncol 2005, A Fleissig et al Lancet Oncol 2006, MA Sidhom et al Lancet Oncol 2006, CS Sternberg et al BJU int 2007, LE Horvath et al Lancet Oncol 2010, J Walsh et al BMC Heakth Serv Res 2010, EM Kesson et al BMJ 2012